Status:
COMPLETED
A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis
Lead Sponsor:
Alnylam Pharmaceuticals
Conditions:
TTR-mediated Amyloidosis
Eligibility:
All Genders
18-90 years
Phase:
PHASE2
Brief Summary
The purpose of this study was to evaluate the safety and clinical activity of long-term dosing with revusiran (ALN-TTRSC). Dosing has been discontinued; patients are being followed-up for safety.
Eligibility Criteria
Inclusion
- Subjects who previously received and tolerated revusiran (ALN-TTRSC) in the ALN-TTRSC-002 study
- Adequate liver function
- Not Pregnant or nursing
Exclusion
- Inadequate renal function
- Uncontrolled hypertension, ischemic heart disease or clinically significant cardiac arrhythmia
- Untreated hypo- or hyperthyroidism
- Prior major organ transplant
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 22 2017
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT02292186
Start Date
October 1 2014
End Date
February 22 2017
Last Update
July 9 2020
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Trial Site
Boston, Massachusetts, United States, 02155
2
Clinical Trial Site
New York, New York, United States, 10034
3
Clinical Trial Site
Cleveland, Ohio, United States, 44195
4
Clinical Trial Site
Calgary, Alberta, Canada